Is Radiopharm Theranostics Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: RADX) stock is to Strong Buy RADX stock.
Out of 1 analyst, 1 (100%) are recommending RADX as a Strong Buy, 0 (0%) are recommending RADX as a Buy, 0 (0%) are recommending RADX as a Hold, 0 (0%) are recommending RADX as a Sell, and 0 (0%) are recommending RADX as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year RADX price target, the average RADX price target is $16.00, with the highest RADX stock price forecast at $16.00 and the lowest RADX stock price forecast at $16.00.
The Wall Street analyst predicted that Radiopharm Theranostics's share price could reach $16.00 by Dec 16, 2026. The average Radiopharm Theranostics stock price prediction forecasts a potential upside of 300% from the current RADX share price of $4.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.